NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 190,476 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $21.50, for a total value of $4,095,234.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
NewAmsterdam Pharma Trading Down 0.1 %
NewAmsterdam Pharma stock opened at $22.70 on Thursday. NewAmsterdam Pharma has a 1-year low of $5.63 and a 1-year high of $26.35. The firm has a 50-day moving average of $21.52 and a 200-day moving average of $14.04.
Analyst Ratings Changes
NAMS has been the topic of several recent analyst reports. Royal Bank of Canada increased their target price on shares of NewAmsterdam Pharma from $25.00 to $31.00 and gave the stock an "outperform" rating in a research note on Thursday, February 29th. Guggenheim began coverage on NewAmsterdam Pharma in a report on Thursday, January 18th. They issued a "buy" rating and a $30.00 price objective for the company. Piper Sandler began coverage on NewAmsterdam Pharma in a report on Tuesday, January 16th. They set an "overweight" rating and a $37.00 price objective on the stock. Finally, Scotiabank started coverage on NewAmsterdam Pharma in a research note on Thursday, March 14th. They issued a "sector outperform" rating and a $35.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $31.00.
Biden replacement revealed?
From Paradigm Press | Ad
A former CIA insider just announced a disturbing prediction…
Biden will withdraw as the Democrat nominee on June 13.
See his shocking evidence in this new report
Read Our Latest Stock Report on NAMS
Institutional Trading of NewAmsterdam Pharma
Several hedge funds have recently bought and sold shares of the stock. Fcpm Iii Services B.V. purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $132,157,000. Goldman Sachs Group Inc. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $15,463,000. Opaleye Management Inc. purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $2,964,000. Parkman Healthcare Partners LLC lifted its position in NewAmsterdam Pharma by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company's stock valued at $3,359,000 after buying an additional 51,726 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in NewAmsterdam Pharma by 987.5% during the fourth quarter. Royal Bank of Canada now owns 10,875 shares of the company's stock valued at $121,000 after purchasing an additional 9,875 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company's stock.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
